Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03715153 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
A Phase 3 study, sponsored by Institut de Recherches Internationales Servier.
- Terminated
- Registry status
- Phase 3
- Development phase
- 211
- Enrollment target
NCT03715153 is a Phase 3 study that was terminated before completion, run by Institut de Recherches Internationales Servier. The registered enrollment target is 211 participants.
The verdict
NCT03715153, a Phase 3 study, was terminated before completion, sponsored by Institut de Recherches Internationales Servier.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 211 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacity and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.
Interventions
- DRUG BUMETANIDE (S95008) for week 0 - 26
- DRUG PLACEBO for week 0 - 26
- DRUG Open-Label BUMETANIDE (S95008) for weeks 26 - 52
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2021-10-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03715153
The ClinicalTrials.gov registry entry for NCT03715153 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BUMETANIDE (S95008) for week 0 - 26 is the first listed.
NCT03715153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03715153 about?
NCT03715153 is a clinical study titled "Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.". The purpose of this study was to evaluate the efficacity and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.
What is the current status of trial NCT03715153?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 211 participants. The study started on 2018-10-04. Estimated completion is 2021-10-26.
What interventions are being tested in trial NCT03715153?
The interventions under investigation include: BUMETANIDE (S95008) for week 0 - 26 (DRUG), PLACEBO for week 0 - 26 (DRUG), Open-Label BUMETANIDE (S95008) for weeks 26 - 52 (DRUG).
Who is sponsoring clinical trial NCT03715153?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.